Zur Person

Dr. Rudolf Prager

Meine medizinische Karriere begann 1977. Nach einer kurzen Ausbildung auf einem theoretischen Institut wurde ich von 1978 bis 1984 zum Facharzt für Innere Medizin ausgebildet und habe mich dabei sehr früh auf Diabetes und Stoffwechsel spezialisiert. Im Rahmen eines Forschungsaufenthaltes in den USA 1984/85 entwarf ich grundlegende Arbeiten für meine spätere Habilitation.

Nach meiner Rückkehr übernahm ich 1986 die Leitung der Stoffwechselabteilung der II. Med. Univ. Klinik und wurde 2000 zum Leiter der 3. Med. Abteilung für Stoffwechselmedizin und Nephrologie am KH Hietzing ernannt. Diese Abteilung mit über 20 Ärzten ist eine der größten Stoffwechselabteilungen Österreichs.

Im Zuge meiner leitenden Funktion am Karl-Landsteiner-Institut für Stoffwechselerkrankungen und Nephrologie betreibe ich klinische Studien zu neuen medikamentösen Therapien auf dem Gebiet des Diabetes, der Hochdruckbehandlung und der Nephrologie.

Stoffwechselzentrum im Rudolfinerhaus

Gemeinsam mit Univ.-Prof. Dr. Anton Luger vom AKH wird derzeit ein Stoffwechsel- und Hormonzentrum im Rudolfinerhaus eingerichtet. Hier werden künftig neben Stoffwechselerkrankungen auch hormonelle Erkrankungen sowie Bluthochdruck auf dem neuesten Stand der Forschung behandelt werden können.

Ausbildung

  • Volksschule in Weißenkirchen

  • Mittelschule Piaristengymnasium Krems

  • Matura Juni 1971

  • Medizinstudium an der Universität Wien 1971 bis 1976

  • Promotion zum Dr. med.univ. am 21.12.1976

Additivfachärzte  und Zusatzausbildungen

  • Additivfacharzt für Endokrinologie und Stoffwechsel

  • Additivfacharzt für Nephrologie

  • Prüfärztediplom der Wiener Ärztekammer

Publikationen

Übersichtsarbeiten
  1. Punzengruber C, Prager R, Kolassa N, Winkler F, Suko J : Calcium gradient dependent and calcium gradient independent phosphorylation of sarcoplasmic reticulum by orthophosphate . The role of magnesium. Eur. J. Biochem.; 92: 349 – 359. 1978
  2. Schernthaner, G., Matha, R., Sehnal, E., Prager, R. Prolactin, growth hormone, C-peptide, insulin and glucose tolerance following acetylsalicylic acid administration in maturity onset diabetics. Acta Endocrinologica; 91: 314. 1979
  3. Prager R, Punzengruber C, Kolassa N, Winkler F, Suko J : Ionized and bound calcium inside isolated sarcoplasmic reticulum of skeletal muscle and its significance in phosphorylation of adenosine triphosphatase by orthophosphate. Eur. J. Biochem.; 97: 239 – 250. 1979
  4. Schernthaner G, Müller MM, Prager R, Mühlhauser I : Die klinische Bedeutung des Glycohämoglobins ( HbA1 ). Wien. klin. Wschr.; 92: 1-11. 1980
  5. Prager R, Schernthaner G, Müller MM : HDL – Cholesterin und Diabetes mellitus. Analyse von Diabetestyp, Therapieform, Diabetesdauer und Stoffwechselkontrolle. Wien. klin. Wschr., 92: 672 – 677. 1980
  6. Kuzmits R, Schernthaner G, Mühlhauser I, Prager R, Müller MM : Metabolismus der Schilddrüsenhormone und diabetische Stoffwechselkontrolle. Bulletin S.S.C.C./ S.G.K.C.; 21: 170- 178. 1980
  7. Prager R, Schernthaner G, Mühlhauser I, Müller MM . Einfluss von Diabetestyp, Stoffwechselkontrolle ( HbA1 ), Therapieform und Diabetesdauer auf HDL – Cholesterin und Plasmalipide bei Typ – I und Typ – II Diabetes mellitus. Verh. Dt. Ges. Inn. Med.; 96: 991 – 994. 1980
  8. Prager R, Schernthaner G, Meisinger V, Mühlhauser I, Müller MM : Hypomagnesiämie – ein möglicher Angiopathierisikofaktor – und metabolischer Kontrollgrad bei Diabetes mellitus. Acta med. Austriaca; 7: 203 – 204. 1980
  9. Prager R, Schernthaner G, Kostner CM, Mühlhauser I, Dieplinger H, Lang PD : Plasmalipide, Lipoproteine, Apolipoproteine und LCAT bei Diabetes mellitus : eine Doppelblind Crossover Studie mit Bezafibrat. Verb.Dt.Ges.Inn.Med.; 7: 992 – 995. 1981
  10. Klein K, Sinzinger H, Schernthaner G, Silberbauer K, Prager R : Plättchensensitivitat fur Prostacyclin ( PG 12 ) bei Patienten mit juvenilem Diabetes mellitus. klin. Wschr.; 93: 460 – 462. 1981
  11. Laggner P, Suko J, Punzengruber C, Prager R : Electron spin resonance studies on conformational changes of the sarcoplasmic reticulum Ca2 – ATPase induced by synergistic action of calcium and ATP. Zeitschr. f. Naturforschung; 36b: 1136- 1143. 1981
  12. Schernthaner, G., Prager, R., Weissel, M., Hofer, R: Decreased insulin receptor number in thyrotoxicosis. Annales d’Endocrinologie; 43: 992-995. 1982
  13. Prager R, Schernthaner G, Kostner GM, Mühlhauser I, Zechner R, Dorda W : Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins Al, All and B and LCAT activity in hyperlipidemic, non insulin dependent diabetics. Artherosclerosis; 43: 321 – 327. 1982
  14. Prager R, Schernthaner G, Kostner G, Mühlhauser I, Meisinger V: Hypomagnesiämie bei Diabetes mellitus. Korrelationsanalysen mit Stoffwechselkontrollgrad, Lipidstatus und Thrombozytenfunktion. Akt. Endocrin. Stoffw.: 3: 140 – 143. 1982
  15. Prager R, Schernthaner G : Comparison of insulin receptor binding to monocytes and erythrocytes in newly diagnosed type II diabetes mellitus. metab. Res.; 14: 561-563, 1982
  16. Luger A, Graf H, Prager R, Stummvoll HK : L’hemofiltration continue sur membrane de polysulfone. La Nouvelle Presse Medicale ; 11 : 3657, 1982
  17. G : Receptor binding properties of human insulin (recombinant DNA and human proinsulin and their interaction at the receptor site . Diabetes Care; 5: 104 – 106, 1982
  18. Stummvoll HK, Graf H, Ebm W, Luger A, Prager R, Wolf C : Allgemeine internistische Intensivmedizin – erste Erfahrungen an der neu eröffneten Intensivstation der ll. Medizinischen Universitätsklinik Wien. Acta med. Austriaca; 9: 166-169, 1982
  19. Schernthaner G, Graninger W, Kwasny W, Prager R, Otto C : Diabetestherapie mittels kontinuierlicher Insulininfusion durch portale Pumpen : Metabolische Effekte der Kurzzeitbehandlung und Langzeitergebnisse bei Problempatienten . med. Austriaca; 9: 205-213, 1982
  20. Schernthaner, G., Kovarik, J., Prager, R., Willvonseder, R.Growth hormone, prolactin and insulin following arginine infusion in primary hyperparathyroidism before and after parathyroidectomy. Acta Endocrinologica; 104: 206-209. 1983
  21. Graf H, Stummvoll HK, Luger A, Prager R: Effect of amino acid infusion on glomerular filtration rate. N. Engl. J. Med.; 308: 159-160, 1983
  22. Prager R, Schernthaner G: Insulin binding of human and porcine monocomponent insulin to monocytes in type I ( insulin dependent ) diabetic patients and control subjects. Diabetologia; 25: 235-237, 1983
  23. Prager R, Kovarik J, Schernthaner G, Woloszczuk W, Willvonseder R: Peripheral Insulin Resistance in Primary Hyperparathyreoidism. Metabolism: 32; 800-805. 1983
  24. Prager, R., Schernthaner, G., Matha, R: Metformin does not alter insulin receptor binding in non insulin dependent diabetes mellitus. Acta Endocrinologica; 102 (253), pp. 76-77. 1983
  25. Schernthaner G, Kovark J, Prager R, Willvonseder R: Growth Hormone, prolactin and insulin following arginine infusion in primary hyperparathyreoidism before and after parathyeroidectomy. Acta Endocrinologica; 104: 206-209. 1983
  26. Stummvoll HK, Graf H, Luger A, Prager R: Spontaneous arteriovenous plasma separation. Critical Care Medicine; 10: 1983
  27. Graninger W, Prager R, Schernthaner G: Einfluss der kontinuierlichen Insulininfusion mittels tragbarer, programmierbarer Insulinpumpen auf das Insulinrezeptorverhalten. Dt.Ges.Inn.Med.; 89: 721-723. 1983
  28. Schernthaner G, Kostner GM, Dieplinger H, Prager R, Mühlhauser I: Apolipoproteins (AI, AII, B), lipoprotein (a) and lecithin cholesterol – acetyltransferase activity in diabetes mellitus. Atherosclerosis; 49: 277–293. 1983
  29. Prager R, Schernthaner G : Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metformin treatment . Results of a double blind cross over study in type II diabetics. Diabetes; 32: 1083-1086. 1983
  30. Ertl L, Prager R : Gesichts – und Mediastinalemphysem im Anschluss an Zahnextraktion. Österr. Z. Stomatol. SO; 340-342. 1983
  31. Luger A, Graf H, Prager R, Stummvoll HK : Die kontinuierliche arteriovenöse Hämofiltration als Therapie der akuten Niereninsuffizienz . Klin. Wschr.; 96: 1-4. 1984
  32. Prager R, Schernthaner G, Kovarik J, Cichini G, Klaushofer K, Willvonseder R : Primary hyperparathyreoidism is associated with decreased insulin receptor binding and glucose intolerance. Tissue Int.; 36: 253-258. 1984
  33. Luger A, Graf H, Prager R, Stummvoll HK : Alterations in the renin – angiotensin -aldosterone system in the critically Ill . Hor metabol. Res.; 16: 213-214. 1984
  34. Schernthaner G, Prager R : Insulinrezeptor – und Postrezeptorstörungen : Bedeutung für Entstehung und Therapie von Kohlenhydratstoffwechselstörungen. Acta med. Austriaca; 1: 70-77. 1984
  35. Schernthaner G, Prager R, Weissel M, Höfer R : Decreased insulin receptor binding in hyperthyreoidism. Wschr.; 62 : 1074-1080. 1984
  36. Schernthaner G, Prager R, Punzengruber C, Luger A : Severe hyperprolactinaemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia; 28: 138-142. 1985
  37. Graf H, Prager R, Kovarik J, Luger A, Schernthaner G, Pinggera WF: Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis . Metabolism; 34 : 974-977. 1985
  38. Prager R, Schernthaner G, Graf H, Chichini G, Luger A : Influence of acute experimental hypercalcemia on peripheral insulin sensitivity in healthy subjects . Diabetes Research; 3 : 199-200. 1986
  39. Prager R, Schernthaner G, Graf H : Effect of metformin treatment on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes & Metabolism; 12 : 346-350. 1986
  40. Prager R, Wallace P, Olefsky JM : In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J. Clin. Invest.; 7S: 472-481. 1986
  41. Baron A, Wallace P, Brechtel G, Prager R: Somatostatin does not increase Insulin-stimulated Glucose Uptake in Humans. Diabetes; 36: 33–36. 1987
  42. Prager R, Wallace P, Olefsky JM : Hyperinsulinemia Does not compensate for peripheral Insulin Resistance in Obesity. Diabetes; 36: 327–334. 1987
  43. Bergman RN, Prager R, Volund A, Olefsky JM : Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic Glucose clamp. J. Clin. Invest.; 79: 790-800. 1987
  44. Prager R, Wallace P, Olefsky JM : Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes; 36: 607-610, 1987
  45. Bratusch Marrain P, Prager R, Kacerovsky-Bielesz G, lrsigler K, Borkenstein M, Biesenbach G, Kitzler P, Hopferwieser Th, Pretsch I, Sulzer M : Stand der Betreuung der Typ – I -Diabetiker in Österreich. Klin.Wschr.; 100: 442-449. 1988
  46. Klauser R, Schernthaner G, Prager R : Mixtures of human intermediate and human regular insulin in type I diabetic patients. Diabetes Research and Clinical Practice; 5: 185-190. 1988
  47. Prager R : Pathogenese und Therapie des Diabetes mellitus Typ I und Typ II. med. Wschr.; 138: 337-340. 1988
  48. Schnack C, Prager R, Winkler J, Klauser R, Schernthaner G : Effects of 8 Wk a-Glucosidase inhibition on metabolic control, c – peptid secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type II Diabetic patients. Diabetes Care; 12: 537-543. 1989
  49. Prager R : Therapie der Hyperlipidämie mit HMG – CoA – Reduktasehemmern. Wien.med. Wschr.; 139: 17-20. 1989
  50. Klauser R, Mühlbacher F, Gnant M, Prager R, Brauner E, Pacini G, Kovarik J : Pancreatic transplantation with venous portal drainage. Lancet; 988. 1989
  51. Klauser R, Prager R, Watschinger B, Schernthaner G : Metabolic effects of biosynthetic human proinsulin in type II diabetes mellitus. Europ. Clin. Invest.; 19: 466-479. 1989
  52. Prager R, Schernthaner G, Niederle B, Roka R: Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyreoidism before and after surgery. Calc. Tissue Intern; 46: 1-4, 1990
  53. Kueenburg H, Brunnbauer M, Watzinger U, Winter F. Müller MM, Graf H., Prager R. : Die Wertigkeit von Fruktosamin bei Hämodialysepatienten. Wien. Klin. Wschr.; 102: 11-13. 1990
  54. Brunnbauer M, Kuenburg E, Winter F, Müller MM, Prager R : Tageszeitliche Schwankungen von Fruktosamin bei Patienten mit Typ – II Diabetes mellitus . Wien. Klin. Wschr.; 102: 72-73, 1990
  55. Hartter E, Svoboda T, Leil B, Schuller M, Ludvik B, Woluzczuk W, Prager R : Reduced islet – amyloid polypeptide in insulin – dependent diabetes mellitus. Lancet; 854. 1990
  56. Prager R : Warum das Insulin beim Typ – 2 Diabetiker nicht richtig zur Wirkung kommt. Diabetesjournal; 6: 6-9, 1990
  57. Klauser R, Speiser P, Gisinger C, Schernthaner G, Prager R : Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus. J. Cardiovasc. Pharmacol.; 15: 93-96,1990
  58. Mühlbacher F, Gnant MFX, Auinger M, Steininger R, Klauser R, Prager R, Karnel F : Pancreatic venous drainage to the portal vein: A new method in human pancreas transplantation. Transplantiation Proceedings; 22: 636-637. 1990
  59. Luger A, Prager R, Gaube S, Graf H, Klauser R, Schernthaner G : Decreased peripheral insulin sensitivity in acromegalic patients. Exp. Clin. Endocrinol.; 95: 339-343. 1990
  60. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kueenburg E, Brunnbauer M, Woloszczuk W, Prager R : Basal and stimulated plasma levels of pancreatic amylin indicate its co – secretion with insulin in humans. Diabetologia; 34: 52-54.1991
  61. Sachs G, Spiess K, Moser G, Prager R, Kunz A, Schernthaner G : Glykosiliertes Hämoglobin und Glukose – Selbstmonitoring ( Compliance ) bei depressiven und nicht depressiven Typ 1- Diabetikern. , Psychosom. med. Psychol.; 41: 306-312. 1991
  62. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C Kueenburg E, Schernthaner G : Metabolic Effects of Isradipine vs. Hydrochlorothiazide in Diabetes mellitus. Hypertension; 1: 15-21. 1991
  63. Prager R, Ludvik B, Hartter E : Die Rolle von Amylin in der Pathogenese des Typ- II-Diabetes mellitus. Acta Medica Austriaca IS; 61-62. 1991
  64. Mihaljevic R, Bratusch-Marrain P, Hoffmann H, Langmayr N, Prager R : Patientengerechte Insulinapplikation bei Typ II- Diabetikern. Therapiewoche Österreich; 6: 487-496. 1991
  65. Klauser R, Prager R, Schernthaner G, Olefsky JM : Contribution of postprandial insulin and glucose to glucose disposal in normal and insulin-resistant obese subjects. Clin. Endocrin. Metab.: 73: 258-264. 1991
  66. Watschinger B, Brunner Ch, Schnack Ch, Prager R, Weissel M, Burghuber OC : Left and right ventricular function in normotensive type I diabetic patients. Cardionephrology; 88: 115-118. 1991
  67. Ludvik B, Lell B, Hartter E, Schnack C, Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes mellitus. Diabetes; 40: 1615-1619. 1991
  68. Ludvik B, Kuenburg E, Brunnbauer M, Schernthaner G, Prager R : The Effects of Ramipril on Glucose Tolerance, Insulin Secretion, and insulin Sensitivity in patients with Hypertension. J. Cardiovasc. Pharm.; 18: 157-159. 1991
  69. Virgolini I, Angelberger P, Banyai M, Knöbl P, Pantev T, Neuhold N, Prager R, Sinzinger H: 123 I- tyrosine- ( A 14 )-insulin: preparation and preliminary clinical studies. klin. Wschr.; 103: 657-660. 1991
  70. Ludvik B, Kautzky-Willer A, Prager R : Epidemiologie, Ätiologie und neue therapeutische Konzepte bei Adipositas. Therapiewoche Österreich; 7: 10-16. 1992
  71. Kautzky-Willer A, Pacini G, Niederle B, Schernthaner G, Prager R: Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyreoidism before and after surgery. Clinical Endocrinology; 37: 147-155. 1992
  72. Niederle B, Stamm L, Längle F, Schubert E, Woluszczuk W, Prager R : Primary hyperparathyreoidism in Austria: Results of an 8 year prospective study. World J. Surgery; 16: 777-783. 1992
  73. Kautzky-Willer A, Pacini G, Ludvik B, Schernthaner G, Prager R: B cell hypersecretion and not reduced hepatic extraction causes hyperinsulinemia in obese nondiabetic subjects. Metabolism; 41: 1304-1312.1992
  74. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R : Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia; 36: 84-87,1993
  75. Prager R : Amylin und Typ II-Diabetes. Diabetes und Stoffwechsel; 2: 40-43. 1993
  76. Kautzky-Willer A, Niederle B, Schernthaner G, Prager R: Diabetes mellitus und Kohlenhydratstoffwechsel beim primaren Hyperparathyreoidismus. Wien. Klin. Wschr.; 105/6: 158-162. 1993
  77. Watschinger B, Brunner Ch, Wagner A., Schnack Ch, Prager R, Weissel M, Burghuber OC : Left ventricular diastolic Impaired in type I diabetic patients with microalbuminuria. Nephron; 63: 145-151. 1993
  78. Prager C, Streli C. Prager R : Diabetes und Sport Wr. Med. Wschr.; 143: 9-12. 1993
  79. Kautzky-Willer A, Pacini G, Weissel M, Capek M, Ludvik P, Prager R: Elevated hepatic insulin extraction in essential hypertension. Hypertension; 21: 646-653. 1993
  80. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Müller M: Thrombogenic factors are related to urinary albumin excretion rate in type I (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia; 36: 1045-1050. 1993
  81. Kautzky-Willer A, Endler AT, Streli C, Graf H, Prager R: Glycated hemoglobin in hemodialysis patients with and without erythropoietin substitution: a method comparison. Klin. Lab.; 39: 1046. 1993
  82. Sachs G, Spiess K, Moser G, Kautzky-Willer A, Lugner A, Pietschmann P, Schernthaner G, Prager R : Hormonal and blood glucose responsiveness as an indicator of specific emotional arousal in Type I diabetics. J. Psychosom. Res.; 37: 831-842, 1993
  83. Kautzky-Willer A, Tomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W, Prager R: Role of islet amyloid polypeptide secretion in insulin resistant humans. Diabetologia; 37: 188-194,1994
  84. Schnack Ch, Capek M, Banyai M, Kautzky-Willer A, Prager R , Schernthaner G: Long term treatment with nifedipine reduces urinary albumin excretin rate in treatment in normotensive type-1 diabetic patients with microalbuminuria. Acta Diabetologica Latina; 31: 14-18,1994
  85. Schnack Ch, Pietschmann P, Knöbl P, Schuller E, Prager R, Schernthaner G : Apolipoprotein ( a ) levels and artherogenic lipid fractions in relation to the degree of urinary albumin excretion in type 2 diabetes mellitus . Nephron; 66: 273-277, 1994
  86. Knöbl P, Pietschmann P, Schnack C, Prager R, Schernthaner G: Apolipoprotein (a) levels in patients with type I diabetes mellitus are unrelated to metabolic control or vascular disease. Wien.klin.Wschr.; 106: 728-732, 1994
  87. Ludvik B, Lell B, Hartter E, Stifter S, Graf H, Prager R: Increased of circulating amylin in patients with chronic renal failure have no effect on insulin secretion. Clin.Invest.; 94: 2045-2050, 1994
  88. Spiess K, Sachs G, Frischenschlager O, Moser G, Schernthaner G, Prager R: Zur phasenspezifischen Funktion der Vorbeugung beim Typ I Diabetes- Patienten nach Krankheitsausbruch. Psychosom. Med Psychoanal.; 40: 52-67,1994
  89. Spiess K, Sachs G, Moser G, Pietschmann P, Schernthaner G, Prager R: Psychological moderator variables and metabolic control in recent onset type I diabetic patients – a two year longitudinal study. J Psychosom. Res.; 38: 249 – 258. 1994
  90. Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R: Effect of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria. Clin. Investig.; 72: 961-966,1994
  91. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T: Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Haemostas.; 71: 692-697, 1994
  92. Prager R: Diabetes state of the art. Ungelöste Probleme und Zukunftsperspektiven. Hausarzt; 5: 6-8. 1994
  93. Prager R: Stufentherapie des Diabetes mellitus Typ II. Forum Dr. Med.; 1842-45.1994
  94. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, Prager R: Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney International; 47: 200-206. 1995
  95. Griesmacher A, Kindhauser M, Andert S, Schreiner W, Toma C,Knöbl P, Pietschmann P, Prager R, Schnack C, Schernthaner G, Müller MM : Enhanced serum levels of thiobarbituric-acid reactive substances in diabetes mellitus. J. Med.; 98: 469 – 475. 1995
  96. Prager R: Adipositas: Physiologie und Behandlungsmöglichkeiten. Acta med. Austriaca; 22: 94-95. 1995
  97. Geyer G, Haidinger G, Francesconi M, Langmayr N, Prager R, Schoberberger R, Toplak H, von Kalkreuth G, Kunze M: Der Einfluss von Dexfenfluramin auf Essverhalten und Körpergewicht von Adiposenergebnissen einer Anwendungsstudie von Isomeride in österreichischen Artzpraxen. Acta med. Austriaca; 22: 95-109. 1995
  98. Spiess K, Sachs P, Pietschmann P, Prager R:  Program to reduce onset distress in unselected type I diabetic patients : effects on psychological variables and metabolic control. Europ. Endocrinol.; 132: 580-586. 1995
  99. Thomaseth K, Kautzky-Willer A, Ludvik B,  Prager R,  Pacini G: An integrated mathematical model to assess B-cell activity during the oral glucose test. J.of Physiol.; 270: 522-531. 1996
  100. Kotzmann H, Linkesch M, Ludvik B, Clodi M, Luger A, Schernthaner G, Prager R, Klauser R: Effect of danazole-induced hyperglucagonemia on glucose tolerance. Europ.J.of Clini.lnvest.; 25: 942-947. 1996
  101. Kautzky-Willer A, Tomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R, Pacini G: Dexamethasone treatment enhances beta cell activity in healthy humans. Metabolism; 45: 486-491. 1996
  102. Bamas U, Schmidt A, Illievich A, Kiener HP, Rabensteiner D, Kaider A, Prager R, Abrahamian H, lrsigler K, Mayer G: Evaluation of risk factors for the development of nephropathy in patients with IDDM: insertion/deletion angiotensin converting enzyme gene polymorphism, hypertension and metabolic control. Diabetologia; 40: 327-331. 1997
  103. Tomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ, Prager R, Olefsky JM, Ludvik B: Amylin release during oral glucose tolerance test. Diabetic Medicine; 14: 29-34.1997
  104. Ludvik B, Kautzky-Willer A, Prager R, Tomaseth K, Pacini G.: Amylin, History and overview. Diabetic Medicine; 14: 9-13. 1997
  105. Kautzky-Willer A, Tomaseth K, Ludvik B, Nowotny P, Rabensteiner D, Waldhäusl W, Pacini G, Prager R: Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes; 46: 607-614. 1997
  106. Kautzky-Willer A, Prager R, Waldhäusl W, Pacini G, Tomaseth K, Wagner OF, Ulm M , Streli C, Ludvik B: Pronounced insulin resistance and inadequate 6 cell secretion characterize lean gestational diabetes mellitus during and after pregnancy. Diabetes Care; 20: 1619-1623. 1997
  107. Clodi M, Thomaseth K, Pacini G, Hermann A, Kautzky-Willer A, Waldhäusl W, Ludvik B, Prager R: Distribution and kinetics of amylin in humans. J.Physiol.; 274: 903-908. 1998
  108. Fliser D, Pacini G, Engelreiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and Hyperinsulinemia in Patients with incipient renal disease. Kidney Intern; 53: 1343-1347. 1998
  109. Rabensteiner D, Abrahamian H, Irsigler K, Hermann K, Kiener H, Mayer G, Kaider A, Prager R: ACE Gene Polymorphismus and Proliferative Retinopathy in type 1 Diabetes. Diabetes Care; 22: 1530-1535. 1999
  110. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. Europ. J.Clini.Invest.; 30: 771-77. 2000
  111. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R und Waldhäusl W: Increased plasma leptin in gestational diabetes. Diabetologia; 44: 164-172. 2001
  112. Ludvik B, Mahdjoobian K, Waldhäusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G: The Effect of Ipomoea batatas (Caiapo) on Glucose Metabolism and Serum Cholesterol in Patients with Type 2 Diabetes. A randomized study. Diabetes Care; 25: 239-240. 2002
  113. Abrahamian H, Prager R: Senkung der kardiovasculären Morbidität und Mortalität durch antihypertensive Kombinationstherapie bei Patienten mit Typ 2-Diabetes mellitus. Med.Wochenschr.; 159: 210-214. 2002
  114. Georg P, Kautzky-Willer A, Mahjoobian K, Hofer A, Prager R, Pacini G, Ludvik B: Influence of Metabolic Control on Splanchnic Glucose Uptake, Insulin Sensitivity, and the Time Required for Glucose Absorption in Patients with Type 1 Diabetes. Diabetes Care; 25: 2042-2047. 2002
  115. Abrahamian H, Schueller A, Mauler H, Prager R, Irsigler K: Transfer of knowledge from the specialist to the generalist by videoconferencing: effect on diabetes care. J Telemed Telecare; 8: 350-355. 2002
  116. Hanusch-Enserer U, Cauza E, Spak M, Dunky A, Rosen HR, Wolf H, Prager R, Eibl MM: Acute-phase response and immunological markers in morbid obese patients following adjustable gastric banding. Int.J.Obes.Relat.Metab.Disord.; 27:  355-361. 2003
  117. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess ß-cell function during OGTT in metabolic disorders. J.Physiol.; 285: E 155-162. 2003
  118. Ludvik B, Tomaseth K, Nolan Jj, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagons secretion in healthy and diabetic human subjects. Europ.J.Clin. Invest.; 33: 316-322. 2003
  119. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R: Effect of Gastric Banding on Aminoterminal Pro-brain Natriuretic Peptide in the Morbidly Obese. Obesity Research; 11: 695-698. 2003
  120. Ludvik B, Waldhäusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of Ipomoea Batatas (Caiapo) in Type 2 Diabetic Patients. Metabolism; 52: 875-880. 2003.
  121. Hanusch-Enserer U, Cauza E, Spak M, Endler G, Dunky A, Tura A, Wagner O, Rosen HR, Pacini G, Prager R: Improvement of Insulin Resistance and Early Atherosclerosis in Patients after Gastric Banding. Obesity Research; 12: 284-291. 2004
  122. Kästenbauer T, Irsigler P, Sauseng S, Grimm A, Prager R: The prevalence of symptoms of sensorimotor and autonomic neuropathy in Type 1 and Type 2 diabetic subjects. J Diabetes Complications ; 18 : 27-31. 2004
  123. Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R: Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther.; 6: 31-37. 2004
  124. Hanusch-Enserer U, Cauza E, Brabant G, Dunky A, Rosen H, Pacini G, Tuchler H, Prager R, Roden M: Plasma ghrelin in obesity before and after weight loss after laparascopical adjustable gastric banding: J.Clin.Endocrinol.Metab.; 89: 3352-3358. 2004
  125. Hanusch-Enserer U, Enserer C, Rosen HR, Prager R: Indikation zur operativen Adipositastherapie. Acta Med Austriaca ; 31 : 125-129. 2004
  126. Stadler M, Prager R: Typ 2 Diabetes mellitus-Screening und Prävention. Acta Med Austriaca; 31: 158-159. 2004
  127. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Therapie mit oralen Antidiabetika. Acta Med Austriaca; 31: 162-163. 2004
  128. Kautzky-Willer A, Lechleitner M, Pieber TR, Prager R, Roden M, Wascher TC, Weitgasser R: Insulintherapie. Acta Med Austriaca; 31: 164-165. 2004
  129. Edlinger R, Auinger M, Prager R: Diabetische Nephropathie. Acta Med Austriaca; 31: 175-178. 2004
  130. Hermann-Arnhof KM, Hanusch-Enserer U, Kästenbauer T, Publig T, Dunky A, Rosen HR, Prager R, Koller U: N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem.; 51: 138-143. 2005
  131. Engl J, Hanusch-Enserer U, Prager R, Patsch JR, Ebenbichler C: Das Metabolische Syndrom: Auswirkungen einer ausgeprägten Gewichtsabnahme mittels chirurgischer Intervention. Wien.Klin.Wschr.;117: 243-254. 2005
  132. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O, Georg P, Prager R, Kostner K, Dunky A, Haber P: The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arch Phys Med Rehabil; 86: 1527-1533. 2005
  133. Funk M, Endler G, Exner M, Marculescu R, Endler L, Abrahamian H, Mauler H, Grimm A, Raith M, Mannhalter C, Prager R, Irsigler K, Wagner O: PAI 1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wschr.; 117: 707-710. 2005
  134. Prager R: Ezetrol® in der Praxis. J Kardiol.; 12: 11-12. 2005
  135. Auinger M, Edlinger R, Prager R: Perionealdialyse bei Patienten mit diabetischer Nephropathie. Wien Klin Wschr.; 117: 1-6. 2005
  136. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R: Efficacy and Safety of Insulin Glulisine in Patients with Type 1 Diabetes. Horm Metab Res 2005; 37: 702-707. 2005
  137. Home, P.D., Rosskamp, R., Forjanic-Klapproth, J., Dressler, A., Bartusch-Marrain, P., Egger, T., Francesconi, M., Irsigler, K., Kazerovsky-Bielesc, G., Pieber, T., Prager, R., Weitgasser, R., Saudek, F., Laursen, H.B., Christensen, C., Hermansen, K., Juhl, H., Soelling, K., Bergkulla, S., Haapamäki, H., Harno, K., Salmela, P., Voutilainen, E., Bringer, J., Charbonnel, B., Charpentier, G., Durlach, V., Gouet, D., Grenier, J.L., Ozenne, G., Penfornis, A., Pinget, M., Rodier, M., Valensi, P., Vexiau, P., Warnet, A., Austenat, E., Beyer, J., Dreyer, M., Haslbeck, M., Ittner, J.R., Landgraf, R., Laube, H., Lembcke, H.J., Liebl, A., Lotz, N., Matthei, S., Palitzsch, K.D., Paschke, R., Usadel, K.H., Raptis, S., de Heide, L.J.M., van Hoogenhuijze, J., Lutterman, J.A., Spooren, P.F.M.J., Dyrbekk, D., Vaaler, S., Berne, C., Eriksson, J., Lins, P.E., Diem, P., Gaillard, R., Gray, R.S., Thow, J.C., Reckless, J., Sampson, M., Tindall, H. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes/Metabolism Research and Reviews; 21: 545-553. 2005
  138. Stadler M, Anderwald Ch, Karer T, Tura A, Kästenbauer T, Auinger M, Bieglmayer Ch, Wagner O, Kronenberg F, Nowotny P, Pacini G, Prager R: Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas Transplantation. Diabetes Care; 29: 1031-1038. 2006
  139. Kästenbauer T, Wassermann J, Krippl E, Prager R, Irsigler K: Measurement of the walking duration with therapeutic shoes in neuropathic diabetic patients by a novel device (Show-me). Diab Care; 29: 1456. 2006
  140. Stadler M, Auinger M, Anderwald C, Kästenbauer T, Kramar R, Feinböck C, Irsigler K, Kronbenberg F, Prager R: Long-Term Mortality and Incidence of Renal Dialysis and Transplantation in Type 1 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism; 91: 3814–3820. 2006
  141. Kollerits B, Auinger M, Reisig V, Kästenbauer T, Lingenhel A, Irsigler K, Prager R, Kronenberg F: Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diab Care; 29: 1661-63. 2006
  142. Kautzy-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U, Prager R, Pacini G: Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under Metformin and thiazolidinedione. Diabetes Obes Metab.; 8: 561-567. 2006
  143. Stadler M, Auinger M, Anderwald C, Kästenbauer T, Kramar R, Feinböck C, Irsigler K, Kronenberg F, Prager R: Long-term mortality and incidence of renal dialysis and transplantation in type 1 diabetes mellitus. J Clin Endocrinol Metab.; 91: 3814-20. 2006
  144. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irisgler K, Wagner O.F: Association of Low-Grade Inflammation with Nephropathy in Type 2 Diabetic Patients: Role of Elevated CRP-Levels and 2 Different Gene-Polymorphisms of Proinflammatory Cytokines. Exp Clin Endocrinol Diabetes 2007; 115 : 38-41. 2007
  145. Hanusch-Enserer U, Ghatei Mohammed A., Cuaza E, Bloom Steven R., Prager R, Roden M: Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery. Wien Klin Wochenschr.; 119: 291-296. 2007
  146. Nauck, M.A., Meininger, G., Sheng, D., Terranella, L., Stein, P.P., Tesone, P., Davis, T., Colagiuri, S., Prager, R., Schernthaner, G., Toplak, H., Wascher, T., Coucke, F., De Meulemeester, M., Ducobu, J., Gross, J., Zanella, M.T., Godoy, G., Hernandez, E., Profozic, V., Kvapil, M., Tomas, B., Umlauf, P., Zemanova, J., Egstrup, K., Hansen, A., Hermansen, K., Eriksson, J., Lahtela, J., Niskanen, L., Salmela, P., Bauduceau, B., Bringer, J., Charpentier, G., Krempf, M., Marre, M., Weryha, G., Adler, J., Bouzo, H., Derwahl, K.M., Hanefeld, M., Kirchberg, H.G., Klausmann, G., Klein, C., Lehmann, R., Nauck, M., Oerter, E., Schulze, E.D., Weisbrod, A., Weyland, K., Zoller, T., Lam, K., Vadasz, J., Vandorfi, G., Baule, G., DeMattia, G., Gambardella, S., Ghirlanda, G., Lauro, R., Squatrito, S., Zabuliene, L., Chan, S., Mohamed, M., Sauque, L., de Backer, W.A., Wins, E.H.R., Benatar, J., Scott, R., Cooper, J., Furuseth, K., Kulseng, B., Molina, G., Rodriguez, A., Pacheco, E., Markiewicz, K., Pinis, G., Raposo, J., Teles, G., Eng, P., Burgess, L., Moore, R., Wing, J., Calle-Pascual, A., Garcia, S.D., Roca, F.V., Pino, J.L., Puig, J.M., Eizyk, E., Frid, A., Lagerback, P.A., Smith, U., Eddé, M., Saner, H., Chang, C.J., Hwu, C.M., Tu, S.T., Demirtunc, R., Satman, I., Haworth, D., Kopelman, P., Pieters, R., Silvert, B., Watt, R., Ahmann, A., Andrews, S., Barai, L., Barranco, E., Bettis, R., Blank, R., Brazg, R., Brazinsky, S., Bruya, T., Burch, F., Busick, E., Butcher, R., Caos, A., Chen, M., Clower, J., Cohen, K., Collins, G., Cook, J., Davidson, M., Denker, P., Drummond, W., Earl, J., Eisenberg, A., Forker, A., Garcia, R., Geisberg, H., Gilbert, J., Gilman, R., Gleason, D., Goldberg, R., Goldstein, F., Greco, S., Hollander, P., Jacobs, M., Jain, A., Kaplan, R., Kashyap, M., Kawley, A.F., Kerstein, H., Khronusova, Y., Laffer, C., Lewin, A., Linden, D., Lipetz, R., Littlejohn, T., Lochner, J., Mather, S., McGettigan Jr., J., McNeill, R., Mezitis, N., Mitchell, J., Morales, L., Odugbesan, A., Padget, L., Patel, N., Pratley, R., Reusch, J., Robinson, J., Ruckle, J., Sandberg, M., Schear, M.J., Schumacher, D., Severance, R., Shapiro, J., Shomali, M., Silkiner, D., Simon, H., Smith, P., Stevens, J., Umpierrez, G., Wade, R., Weerasinghe, M., Weinberg, M., Wittmer, B., Yale, S.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism; 9: 194-205. 2007
  147. Anderwald-Stadler, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P, Kästenbauer T, Luger A, Prager R, Anderwald C: Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistanz humans. Am J Physiol.; 293:1393-1398. 2007
  148. Huelsmann M, Neuhold S, Strunk G, Moertl D, Berger R, Prager R, Abrahamian H. Riedl M, Pacher R, Luger A, Clodi M. NT-proBNP has a gigh negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J.; 29: 2259-2264. 2008
  149. Francesconi C, Ebenbicher C, Benesch M, Prager R, Asimi T: Biphasisches Insulinaspart 70 (BIAsp 70, NovoMix®70) in der intensivierten konventionellen Insulintherapie bei Typ-2-Diabetes: Eine österreichische Anwendungsbeobachtung. J Klin Endokrinol Stoffw.; 2: 34-39. 2009
  150. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R, Hülsmann M: Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care Oct; 32: 1890-1895. 2009
  151. Stadler M, Theuer E, Anderwald C, Hanusch-Enserer U, Auinger M, Bieglmayer C, Quehenberger P, Bischof M, Kästenbauer T, Wolzt M, Wagner O, Prager R: Persistent arterial stiffness and endothelial dysfunction following successful pancreas-kidney transplantation Type 1 diabetes. Diabet Med. Oct; 26: 1010-1018. 2009
  152. Stadler M, Prager R: Typ 2 Diabetes Mellitus-Screening und Prävention. Wien Klin Wochenschr.; 121: S8-S9. 2009
  153. Clodi M, Fasching P, Hoppichler F, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Roden M, Schernthaner G, Toplak H, Wascher TC, Weitgasser R: Antidiabetische Therapie bei Typ-2 Diabetes. Wien Klin Wochenschr.; 121: S13-S17. 2009
  154. Lechleitner M, Roden M, Weitgasser R, Ludvik B, Fasching P, Hoppichler F, Kautzky-Willer A, Schernthaner G, Prager R, Wascher TC: Insulintherapie bei Diabetes Mellitus. Wien Klin Wochenschr.; 121/21-22 (Suppl 5): S18-S21. 2009
  155. Auinger M, Edlinger R, Prischl F, Kautzky-Willer A, Prager R, Mayer G, Roden M: Diabetische Nephropathie – Update 2009. Wien Klin Wochenschr; 121/21-22 (Suppl 5): S37-S42. 2009
  156. Stadler M, Fortunat S, Schütz-Fuhrmann I, Rami B, Schober E, Kautzky-Willer A, Weitgasse R, Prager R, Bischof F: Leitlinien Insulinpumpentherapie bei Kindern und Erwachsenen. Wien Klin Wochenschr.; 121/21-22 (Suppl 5): S80-S84. 2009
  157. Ludvik B, Brath H, Wascher T, Toplak H, Expertengruppe der Österreichischen Diabetesgesellschaft: The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus. Wien Klin Wochenschr.; 121: 473-82. 2009
  158. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R, Hülsmann M. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care; 32: 1890-5. 2009
  159. Abrahamian H, Hofmann P, Prager R, Toplak H: Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group). Neuropsychiatr Dis Treat.; 5: 261-266. 2009
  160. Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K: Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J.; 30: 1516-24. 2009
  161. Bohdjalian, A., Ludvik, B., Guerci, B., Bresler, L., Renard, E., Nocca, D., Karnieli, E., Assalia, A., Prager, R., Prager, G.Improvement in glycemic control by gastric electrical stimulation (TANTALUS™) in overweight subjects with type 2 diabetes.Surgical Endoscopy and Other Interventional Techniques; 23: 1955-1960. 2009
  162. Liebl, A., Prager, R., Binz, K., Kaiser, M., Bergenstal, R., Gallwitz, B., Biesenbach, G., Ludvik, B., Prager, R., Pusarnig, S., Binz, K., Felix, B., Gerber, P., Loher, A., Golay, A., Aigner, U., Anderten, H., Arnold, J., Austenat, E., Badenhoop, K., Balke, J., Balks, H.-J., Banse, G., Barakat, A., Behnke, T., Bergmann, K., Biermann, U., Böckmann, G.-U., Böhmer, Mi., Braun, M., Daikeler, R., Dehmel, J., Doerwald, H.-J., Ehlenz, K.-A., Eidenmüller, M., Filz, H.P., Forchheim, W., Gallwitz, B., Gries, A., Großkopf, J., Grüneberg, M., Günther, R., Güntsch, V., Hanefeld, M., Hartl, J., Hermes, S., Herold-Beifuss, R., Hintze, G., Hirschhäuser, B., Hüning, W., Huppertz, W., Huptas, M., Jung, W., Kerum, G., Klausmann, G., Klein, C., Klör, E., Koch, P., Kohlhas, K., Kosch, C., Krakow, D., Langguth, D., Liebl, A., Lueg, A., Marks, H.-J., Maxeiner, S., Meißner, H.-P., Merker, L., Meyer, U., Milek, K., Mölle, A., Müller, B., Müller, U.-A., Nauck, M., Nossek, L., Oerter, E.-M., Oldenburg, J., Paulus, R., Pein, M., Pfeiffer, A., Reichert, D., Rett, K., Ruhnau, K.-J., Sauter, J., Schmidt, J., Scholz, G., Schories, M., Schulze, J., Schuster, A., Schwinn, G., Segiet, T., Segner, A., Simonsohn, M., Steindorf, J., Sterzing, A., Strache, S., Tosch, R., Treichel, H.-C., Usadel, K.H., Vidal, S., von Hübbenet, von Knethen, Wagner, C., Weber, M., Wefelnberg, M., Wendisch, U., Wenzl-Bauer, V., Werry, W., Wizemann, E., Wübbolding, H., Zerth, G., Ziegelasch, H.-J., Zieher, S., Zink, S.Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial Diabetes, Obesity and Metabolism; 11: 45-52. 2009
  163. Califf, R.M., McMurray, J.J., Holman, R.R., Haffner, S.M., Bethel, M.A., Holzhauer, B., Hua, T.A., Belenkov, Y., Boolell, M., Buse, J.B., Buckley, B.M., Chacra, A.R., Chiang, F.-T., Charbonnel, B., Chow, C.-C., Davies, M.J., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G.R., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S.E., Krum, H., Laakso, M., Leiter, L.A., Levitt, N.S., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S.A., Rutten, G.E.H.M., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamás, G., Tognoni, G., Tuomilehto, J., Villamil, A.S., Vozár, J.Effect of valsartan on the incidence of diabetes and cardiovascular events.New England Journal of Medicine; 362: 1477-1490. 2010
  164. Stadler M, Storka A, Theuer EA, Krebs M, Vojtassakova E, Nowotny P, Pacini G, Kästenbauer T, Luger A, Prager R, Wolzt M, Anderwald C: Adipokines in type 1 diabetes after successful pancreas transplantation: normal visfatin and retinol-binding-protein-4, but increased total adiponectin fasting concentrations. Clin Endocrinol.; 72: 763-9. 2010
  165. Stadler M, Anderwald C, Pacini G, Zbýn S, Bromintzer-Schifferl M, Mandl M, Bischof M, Gruber S, Nowotny P, Luger A, Prager R, Krebs M: Chronic peripheral hyperinsulinemia in type 1 diabetic patients after successful combined pancreas-kidney transplantation does not affect ectopic lipid accumulation in skeletal muscle and liver. Diabetes; 59: 215-8. 2010
  166. Holman, R.R., Haffner, S.M., McMurray, J.J., Bethel, M.A., Holzhauer, B., Hua, T.A., Belenkov, Y., Boolell, M., Buse, J.B., Buckley, B.M., Chacra, A.R., Chiang, F.-T., Charbonnel, B., Chow, C.-C., Davies, M.J., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G.R., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S.E., Krum, H., Laakso, M., Leiter, L.A., Levitt, N.S., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S.A., Rutten, G.E.H.M., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamás, G., Tognoni, G., Tuomilehto, J., Villamil, A.S., Vozár, J., Califf, R.M.Effect of nateglinide on the incidence of diabetes and cardiovascular events
    New England Journal of Medicine; 362: 1463-1476. 2010
  167. Neuhold, S., Resl, M., Huelsmann, M., Strunk, G., Adlbrecht, C., Rath, C., Prager, R., Luger, A., Clodi, M., Pacher, R.
    Repeat measurements of glycated haemoglobin A 1c and N-terminal pro-B-type natriuretic peptide: Divergent behaviour in diabetes mellitus
    (2011) European Journal of Clinical Investigation; 41: 1292-1298. 2011
  168. Resl, M., Neuhold, S., Riedl, M., Abrahamian, H., Strunk, G., Prager, R., Clodi, M., Hülsmann, M., Luger, A., Pacher, R.
    NT-proBNP and cardiac events in older diabetic patients
    European Journal of Cardiovascular Prevention and Rehabilitation;          18: 399-405. 2011
  169. Schütz-Fuhrmann, I., Schober, E., Rami, B., Stadler, M., Bischof, M., Fortunat, S., Laimer, M., Weitgasser, R., Prager, R.
    CGM-Continuous Glucose Monitoring – Statement of the Austrian Diabetes Association [Positionspapier des Insulinpumpenausschusses der OEDG zur kontinuierlichen Glukosemessung (CGM – Continuous Glucose Monitoring)]
    (2012) Wiener Klinische Wochenschrift; 1245U8PL2: 120-122. 2012
  170. Stadler, M., Prager, R.
    [Type 2 diabetes mellitus-screening and prevention]. [Typ 2 Diabetes Mellitus – Screening und Prävention.]
    (2012) Wiener klinische Wochenschrift; 124 Suppl 2, pp. 4-6. 2012
  171. Auinger, M., Edlinger, R., Prischl, F., Kautzky-Willer, A., Prager, R., Rosenkranz, A.R., Roden, M., Saemann, M., Clodi, M., Schernthaner, G.
    [Diabetic nephropathy–update 2012]. [Diabetische Nephropathie – Update 2012. Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie unter Mitarbeit von.]
    (2012) Wiener klinische Wochenschrift; 124 Suppl 2: 42-49. 2012
  172. Lechleitner, M., Roden, M., Weitgasser, R., Ludvik, B., Fasching, P., Hoppichler, F., Kautzky-Willer, A., Schernthaner, G., Prager, R., Wascher, T.C.[Insulin therapy of diabetes]. [Insulintherapie bei Diabetes mellitus.]
    (2012) Wiener klinische Wochenschrift; 124 Suppl 2: 17-22. 2012
  173. Stadler, M., Zlamal-Fortunat, S., Schütz-Fuhrmann, I., Rami-Merhar, B., Schober, E., Kautzky-Willer, A., Weitgasser, R., Prager, R., Bischof, M.
    [Guidelines for insulin pump therapy in children and adults]. [Leitlinien Insulinpumpentherapie bei Kindern und Erwachsenen (Für den Ausschuss Insulinpumpentherapie der Österreichischen Diabetesgesellschaft).]
    (2012) Wiener klinische Wochenschrift; 124: 123-128. 2012
  174. Clodi, M., Abrahamian, H.E., Drexel, H., Fasching, P., Hoppichler, F., Kautzky-Willer, A., Lechleitner, M., Ludvik, B., Prager, R., Roden, M., Saely, C., Schernthaner, G., Schober, E., Toplak, H., Wascher, T., Weitgasser, R.
    [Antihyperglycemic Treatment Guidelines for diabetes mellitus type 2]. [Antihyperglykämische Therapie bei Diabetes mellitus Typ 2. Grundsatz Statement.]
    (2012) Wiener klinische Wochenschrift, 124 Suppl 2, pp. 10-16. Cited 2 times.2012
  175. Clodi, M., Resl, M., Neuhold, S., Hülsmann, M., Vila, G., Elhenicky, M., Strunk, G., Abrahamian, H., Prager, R., Luger, A., Pacher, R.
    A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus
    European Journal of Preventive Cardiology: 19 : 944-951. 2012
  176. Resl, M., Clodi, M., Neuhold, S., Kromoser, H., Riedl, M., Vila, G., Prager, R., Pacher, R., Strunk, G., Luger, A., Hülsmann, M.
    Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus
    (2012) Diabetic Medicine; 29 (6), pp. 721-725. Cited 11 times. 2012
  177. Pichler, M., Lautsch, D., Adler, C., Bögl, K., Drexel, H., Eber, B., Fauer, C., Föchterle, J., Föger, B., Gansch, K., Grafinger, P., Lechleitner, M., Ludvik, B., Maurer, G., Mörz, R., Paulweber, B., Pfeiffer, K.P., Prager, R., Stark, G., Toplak, H., Traindl, O., Weitgasser, R.Are there differences in LDL-C target value attainment in Austrian federal states? Yes!(2013) Wiener Medizinische Wochenschrift; 163: 528-535. 2013
  178. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.J Am Coll Cardiol.; 62:1365-72. 2013
  179. Resl M, Vila G, Kraxner R, Pacher R, Luger A, Hülsmann M, Neuhold S, Brath H, Prager R, Clodi M. Estimated glomerular filtration rate and albuminuria: true predictors of cardiovascular events in obese patients with type 2 diabetes? Wien Klin Wochenschr.; 125: 629-33. 2013
  180. Reznik, Y., Huang, S., Petrovski, G., Jovanovska, B., Joubert, M., Gyozo, K., Erszébet, T., Lalic, N., Tildesley, H., Aydin, J., Cohen, O., Konvalina, N., Priestman, B.A., Janicijevic, S., Metzger, M., Corcos, A., Joyce, C., Gibbons, D., Podgorski, G., Podgorska, A., Conway, J.R., MacNair, D., Goldenberg, R., Schlosser, R., Perkins, B., Orszag, A., Kooy, A., Huvers, F., Liebl, A., Guerci, B., Duchesne, L., Bode, B., Nardacci, E.A., Schongar, M.A., Buchs, A., Harmann-Boehn, I., Shuster, T., Ross, S., Filetti, S., Renzi, A., Yale, J.-F., Bergeron, J., Conget, I., Gimenez, M., Distiller, L.A., Landau, S., Weinstock, R.S., Bzdick, S., Singer, J., Shraga-Sluski, I., Schütz-Fuhrmann, I., Prager, R., Mosenzon, O., Cahn, A., Rose, L., Ritter, S., Giorgino, F., Bray, S., Alwani, R.A., Schuur, N.J., Lieverse, A.G., Van Vroenhoven, H., Moreau, F., Hanaire, H., Labrousse, F., Bolli, G.B., Lucidi, P.Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrationsDiabetes Technology and Therapeutics; 16 : 816-818. 2014
  181. Stadler M1, Peric S, Strohner-Kaestenbauer H, Kramar R, Kaestenbauer T, Reitner A, Auinger M, Kronenberg F, Irsigler K, Amiel SA, Prager R.
    Mortality and Incidence of Renal Replacement Therapy in People With Type 1 Diabetes Mellitus-A Three Decade Long Prospective Observational Study in the Lainz T1DM Cohort.
    J Clin Endocrinol Metab.; 99: 4523-3. 2014
  182. Reznik, Y., Huang, S., Petrovski, G., Jovanovska, B., Joubert, M., Gyozo, K., Erszébet, T., Lalic, N., Tildesley, H., Aydin, J., Cohen, O., Konvalina, N., Priestman, B.A., Janicijevic, S., Metzger, M., Corcos, A., Joyce, C., Gibbons, D., Podgorski, G., Podgorska, A., Conway, J.R., MacNair, D., Goldenberg, R., Schlosser, R., Perkins, B., Orszag, A., Kooy, A., Huvers, F., Liebl, A., Guerci, B., Duchesne, L., Bode, B., Nardacci, E.A., Schongar, M.A., Buchs, A., Harmann-Boehn, I., Shuster, T., Ross, S., Filetti, S., Renzi, A., Yale, J.-F., Bergeron, J., Conget, I., Gimenez, M., Distiller, L.A., Landau, S., Weinstock, R.S., Bzdick, S., Singer, J., Shraga-Sluski, I., Schütz-Fuhrmann, I., Prager, R., Mosenzon, O., Cahn, A., Rose, L., Ritter, S., Giorgino, F., Bray, S., Alwani, R.A., Schuur, N.J., Lieverse, A.G., Van Vroenhoven, H., Moreau, F., Hanaire, H., Labrousse, F., Bolli, G.B., Lucidi, P.
    Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations
    (2014) Diabetes Technology and Therapeutics; 16 : 816-818. 2014
  183. Stadler M, Krsak M, Jankovic D, Gobi C, Winhofer Y, Pacini G, Bischof M, Haidinger M, Saemann M, Mühlbacher F, Korbonits M, Baumgartner-Parzer SM, Luger A, Prager R, Anderwald Ch, Krebs M. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery.Clinical Ednocrinology.; 80: 208-13. 2014
  184. Prager, R. Current issues: Hypoglycemia – Great barriers in the insulin therapy of type 2 diabetes and problem-solving approaches [Aktuelles: Hypoglykämie – Große barriere in der insulintherapie des typ-2-diabetes und lösungsansätze]Austrian Journal of Clinical Endocrinology and Metabolism; 8: 120-122. 2015
  185. Efficacy and tolerability of vildagliptin-based versus comparative dual therapy in type 2 diabetes : Results of the Austrian subpopulation of the EDGE study.
  186. Brath H, Bialek C, Gingl E, Resl M, Prager R, Ratzinger M.Wien Klin Wochenschr.; 127(7-8): 250-5. doi: 10.1007/s00508-014-0646-x. Epub 2015 Jan 10. 2015
  187. Pavo N, Wurm R, Neuhold S, Adlbrecht C, Vila G, Strunk G, Clodi M, Resl M, Brath H, Prager R, Luger A, Pacher R, Hülsmann M.
    GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes.Clin Chem.; 62: 1612-1620. 2016.
  188. Resl M, Clodi M, Vila G, Luger A, Neuhold S, Wurm R, Adlbrecht C, Strunk G, Fritzer-Szekeres M, Prager R, Pachr R, Hülsmann M.Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. Heart.; 102: 1963-1968. 2016.
  189. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, Vila G, Strunk G, Clodi M, Luger A, Pacher R, Hülsmann M. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.; 102:1544-51. 2016
  190. Clodi M, Abrahamian H, Drexel H, Fasching P, Föger B, Francesconi C, Hoppichler F, Kaser S, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Fröhlich-Reiterer E, Roden M, Säly C, Schernthaner G, Sourij H, Toplak H, Wascher TC, Weitgasser R.
    Antihyperglycemic treatment guidelines for diabetes mellitus type 2.
    Wien Klin Wochenschr.; 128: 45-53. 2016
  191. Stadler M, Zlamal-Fortunat S, Schütz-Fuhrmann I, Rami-Merhar B, Fröhlich-Reiterer E, Hofer S, Mader J, Resl M, Kautzky-Willer A, Weitgasser R, Prager R, Bischof M. Insulin pump therapy in children, adolescents and adults. Wien Klin Wochenschr.; 128: 188-95. 2016
  192. Schütz-Fuhrmann I, Rami-Merhar B, Hofer S, Stadler M, Bischof M, Zlamal-Fortunat S, Laimer M, Weitgasser R, Prager R.
    CGM-Continuous Glucose Monitoring–Statement of the Austrian Diabetes Associat. Wien Klin Wochenschr.; 128: 184-7. 2016.
  193. Sourij H, Edlinger R, Prischl F, Auinger M, Kautzky-Willer A, Säemann MD, Prager R, Clodi M, Schernthaner G, Mayer G, Oberbauer R, Rosenkranz AR.Diabetic kidney disease – Update 2016. Wien Klin Wochenschr.; 128: 85-96. 2016
  194. Lechleitner M, Roden M, Weitgasser R, Ludvik B, Fasching P, Hoppichler F, Kautzky-Willer A, Schernthaner G, Prager R, Wascher TC.
    Insulin therapy of diabetes. Wien Klin Wochenschr.; 128: 54-61. 2016
  195. Stadler M, Fröhlich-Reiterer E, Prager R.
    Type 2 Diabetes mellitus-screening and prevention: Update 2016.
    Wien Klin Wochenschr.; 128: 41-4. 2016
  196. Stadler M, Fröhlich-Reiterer E, Prager R. Type 2 Diabetes mellitus-screening and prevention: Update 2016]. Wien Klin Wochenschr. ; 128: 41-4. 2016
  1. Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S.Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.Diabetes Obes Metab.; 19: 858-865. 2017
Originalarbeiten als kooperierendes Zentrum
  1. Dargie H, Hildebrand P, riegger G, McMurray J, McMorn S, Roberts J, Zambanini A, Wilding J. A Radomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients with New York Heart Association Functional Class I or II Heart Failure. Journal of the American College of Cardiology;  49: 1696-1704. 2007
  2. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. Oct; 156: 623-32. 2008
  3. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C. Linn T. Once-daily basal insulin glargine versus thrice-daily prandiale insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet; 29: 371:1073-84. 2008
  4. Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab. May; 10: 387-99. 2008
  5. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe : the ERODIAB Prospektive Complications Study (PCS). Diab Care; 31 : 1360-6. 2008
  6. Sjolie AK, Klein R. Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N ; DIRECT Programme Study Group. Effect of candesaratn on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet; 372 : 1385-93. 2008
  7. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK ; DIRECT Programme Study Group. Effect of candesartqan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes : randomised, placebo-controlled trials. Lancet; 372: 1394-402. 2008
  8. Roden M, Huber K; HSP-Projektgruppe; Lipid profiles and therapy status in the secondary prevention of high risk patients with cardiovascular disease and/or diabetes mellitus: the Austrian Hospital Screening Projekt (HSP). Wien Klin Wochenschr., 120: 558-65. 2008
  9. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6); 374: 39-47. 2009
  10. Conget I, Battelino T, Gliménez M, Gough H, Castañeda J; The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy. SWITCH Study Group. Diabetes Technol Ther., 13: 49-54. 2011
  11. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med.; 367: 2204-13. 2012
  12. Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med.; 30: 1298-304. 2013
  13. Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators.Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease .N Engl J Med.; 369: 2492-503. 2013
  14. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group.Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab.; 16: 124-36. 2014
  15. Hommel E, Olsen B, Battelino T, Conget I, Schütz-Fuhrmann I, Hoogma R, Schierloh U, Sulli N, Gough H, Castañeda J, de Portu S, Bolinder J; SWITCH Study Group.Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study.Acta Diabetol.; 5: 845-51. 2014
  16. Aronson R, Cohen O, Conget I, Runzis S, Castaneda J, de Portu S, Lee S, Reznik Y; OpT2mise Study Group.OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes-research design and methods.Diabetes Technol Ther.; 16: 414-20. 2014
  17. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes .N Engl J Med. 2015. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. 2015
  18. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA.; 314: 884-94. 2015
  1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.; 373: 11-22. 2015
  2. Conget I, Castaneda J, Petrovski G, Guerci B, Racault AS, Reznik Y, Cohen O, Runzis S, de Portu S, Aronson R; OpT2mise Study Group.The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study.Diabetes Technol Ther.; 18: 22-8. 2016
  3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med.; 375: 311-22. 2016
  4. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. N Engl J Med.; 376: 1713-1722. 2017
  5. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med.; 377: 839-848. 2017
  6. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators.Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.Lancet Diabetes Endocrinol.; 13: 2213-8587. 2017
  7. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet; 389:1399-1409. 2017
  8. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med.; 377: 1228-38. 2017
Buch & Buchbeiträge
  1. Schernthaner G, Borkenstein M, Mathae R, Mayr WR, Hohenecker J, Prager R, Schober G, Susani M : Semisynthetisches und biosynthetisches Humaninsulin : Immunogenitätsuntersuchungen nach Langzeittherapie bei Typ – I Diabetikern und Bindungsanalysen an praformierten lgG Insulinantikörpern und Insulinrezeptoren. In „Neue Insuline :1.Internationales Symposion 1982 „Herausg. Petersen KG, Schluter KJ, Kerp L.: 140-148. 1982
  2. Graf H, Luger A, Prager R, Stummvoll HK : Stimulation of anti-glomerular basement membrane antibody production by plasma exchange in Good-pastures syndrome. In: 2nd Mitteleuropean Meeting on Nephrology Dialysis and Transplantation . : Barduagnis S, Pitzorno F, Rocco A . Wichtig Editore, Milano 257-259. 1982
  3. Kwasny W, Otto C, Prager R, Knoflach F, Schernthaner G:
    Kombinationstherapie von Insulin und Sulfonylharnstoff (HB 420) bei übergewichtigen, insulinresistenten Typ II-Diabetikern: Analyse von Insulinrezeptorbindung, Insulinsekretion und Stoffwechselkontrollgrad. Kombinationstherapie Insulin/Sulfonylharnstoff, Karger, Hrsg. W.Bachmann und H.Mehnert (München). 1983
  4. Graf H, Stummvoll HK, Prager R, Luger A, Kovarik J : Protein binding and dialysate concentration of aluminum – the major determinants of aluminum kinetics during hemodialysis. Chemical Toxicology and Clinical Chemistry of Metals. S.S. Brown, J. Savory Eds. Academic Press, London – New York; 357-360. 1983
  5. Prager R : Receptor and postreceptor abnormalities in diabetes. In Clinical Immunology International Congress Series 718 Ed. Pruzanski W. Seligmann M. Excerpta Medica, Amsterdam – New York Oxford; 35-41, 1987
  6. Baron AD, Kolterman OG, Prager R, Freidenberg GR, Henry RR, Garvey WT, Olefsky JM : Mechanisms of insulin resistance in obese and type II diabetic subjects. In Diabetes Mellitus : Pathophysiology and Therapy. Ed. Creutzfeld W. And Lefebre P., Springer Verlag Berlin-Heidelberg-New York-London-Paris-Tokyo; 107-126. 1988
  7. Kautzky-Willer A, Capek M, Weissel M, Ludvik B, Prager R, Pacini G: Insulin sensitivity, secretion and hepatic extraction in untreated hypertensive patients. Current Topics in Diabetes research; 250-253. 1993
  8. Pacini G, Tomaseth K, Kautzky-Willer A, Prager R: An integrated mathematical models of islet amyloid polypeptide dynamics. Modeling and control in Biomedical Systems. B.W. Patterson (Ed.) Omnipress, Madison WI,; 377-378. 1994
  9. Tura A, Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G: Modelling beta cell secretion and kinetics of proinsulin during an oral glucose test.Health Sciences simulation 2000, Anderson JK and Katzper M. (Eds.), SCS Press, San Diego, USA 103-108, 2000
  10. Anderwald-Stadler, R. Prager “Typ 2 Diabetes Mellitus”, Buchbeitrag für “Ernährungsmedizin” im Ärztekammer-Verlag (Hrsg. Univ.Prof.Dr. Kurt Widhalm); 2008
  11. Prager: Diabetesmanagement mit Insulinanaloga, Uni-Med, 2008